Cannabichromene

Cannabichromene (CBC) is a non-psychoactive cannabinoid that demonstrates anti-inflammatory and analgesic properties through interaction with TRPA1 channels and CB2 receptors. Preclinical studies show CBC reduces inflammatory markers and pain responses in animal models, though human clinical data remains limited.

Origin & History

Cannabichromene (CBC) is a non-psychoactive phytocannabinoid found in Cannabis sativa L., occurring naturally as cannabichromenic acid (CBCA) and converted to CBC through decarboxylation at temperatures above 93°C. It is extracted using supercritical CO2 or ethanol extraction methods and exists in cannabis as a scalemic mixture of approximately 75% (S)-CBC and 25% (R)-CBC.

Historical & Cultural Context

CBC has no documented standalone historical use in traditional medicine systems, as it was only isolated in 1966 and not distinguished from other cannabis cannabinoids until modern analytical methods. While Cannabis sativa has been used for millennia in Ayurvedic, Chinese, and African traditional medicine for pain and inflammation, CBC's role as a minor constituent was incidental rather than targeted.

Health Benefits

• Anti-inflammatory effects demonstrated in preclinical animal models, though human clinical evidence is lacking
• Analgesic (pain-relieving) properties shown in mouse tetrad assays, awaiting human validation
• Antimicrobial activity observed in laboratory studies, clinical significance unestablished
• Potential endocannabinoid system modulation via enhanced anandamide and 2-AG levels (preclinical evidence only)
• Non-psychoactive profile due to poor CB1/CB2 receptor binding, suggesting therapeutic potential without intoxication

How It Works

Cannabichromene activates TRPA1 (transient receptor potential ankyrin 1) channels and modulates CB2 cannabinoid receptors to produce anti-inflammatory effects. CBC inhibits the uptake of anandamide, an endocannabinoid involved in pain regulation, thereby prolonging its activity. The compound also demonstrates antimicrobial properties by disrupting bacterial cell membrane integrity.

Scientific Research

No published human clinical trials, randomized controlled trials, or meta-analyses exist specifically evaluating CBC as a standalone therapeutic agent (PubMed searches return zero hits for CBC-specific clinical trials). Current evidence is limited to preclinical animal studies demonstrating effects in mouse models, with human data restricted to observational cannabis studies where CBC is a minor component.

Clinical Summary

Current evidence for cannabichromene comes primarily from preclinical animal studies and in vitro laboratory research. Mouse tetrad assays have shown CBC reduces pain responses and inflammation markers, with effects comparable to other cannabinoids. Antimicrobial studies demonstrate activity against various bacterial strains in petri dish experiments. No human clinical trials have been published examining CBC's therapeutic effects, making clinical efficacy and optimal dosing unclear.

Nutritional Profile

Cannabichromene (CBC) is a non-psychoactive phytocannabinoid, not a conventional nutritional ingredient and therefore contains no meaningful macronutrients (0g protein, 0g fat, 0g carbohydrates per typical isolate dose), no dietary fiber, and no classical vitamins or minerals. It is a bioactive compound classified as a terpenophenolic molecule with molecular formula C21H30O2 and molecular weight of 314.46 g/mol. CBC is typically found in Cannabis sativa L. plant material at concentrations of 0.1–1.0% dry weight, generally lower than THC or CBD in most cultivars, though some hemp chemotypes yield up to 3–4% CBC by dry weight. As an isolated compound, it is administered in experimental or supplement contexts at doses ranging from 5–50mg per serving in commercial preparations. Bioavailability: CBC is highly lipophilic (logP estimated ~6), resulting in poor aqueous solubility and low oral bioavailability when unformulated; lipid-based delivery systems, nanoemulsions, or sublingual administration significantly enhance absorption. It undergoes first-pass hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2C9), producing hydroxylated metabolites. No caloric value is attributed to CBC at pharmacologically relevant doses. It does not contribute to recommended daily intake of any nutrient. Primary bioactive relevance is its interaction with TRPA1 and TRPV4 channels, and indirect endocannabinoid tone elevation rather than any nutritional function.

Preparation & Dosage

No clinically studied dosage ranges exist for isolated CBC due to the absence of human trials. Preclinical studies use 3-30 nmol doses in rodents, but these do not translate directly to humans. Commercial cannabis extracts contain 0.1-1% CBC with no standardized dosing guidelines from regulatory bodies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CBD, CBG, THC, anandamide enhancers, TRPV1 modulators

Safety & Interactions

Cannabichromene appears well-tolerated in animal studies with no significant adverse effects reported at therapeutic doses. As a cannabinoid, CBC may interact with medications metabolized by cytochrome P450 enzymes, potentially altering drug levels. Safety during pregnancy and breastfeeding has not been established. Individuals taking blood thinners or sedatives should exercise caution due to potential additive effects.